non hodgkins lymphoma
Recently Published Documents


TOTAL DOCUMENTS

233
(FIVE YEARS 24)

H-INDEX

16
(FIVE YEARS 0)

2021 ◽  
Vol 3 (01) ◽  
pp. 36-38
Author(s):  
Yam Bahadur Roka ◽  
Narayani Roka ◽  
Mohan Karki

The incidence of cerebral metastases has increased over the last few decades mainly due to the successful treatment of extra neural cancers and the prolonged survival of patients. The common causes of metastases are lung, kidney, breast and thyroid cancers. We present an interesting case of cerebral metastases that was managed as cerebral abscess, then as lung metastases before finally arriving to the correct diagnosis of Non-Hodgkin’s Lymphoma.


2021 ◽  
pp. 48-51
Author(s):  
Gunjan S Dalal ◽  
Jyoti Jain ◽  
Atul Singh Rajput

Acute onset polyserositis as a presentation of Non Hodgkins lymphoma(NHL) occurs in 20% of individuals.(1-4) Etiology being a jumble between an Extranodal Burkitt lymphoma(ENBL),a pyothorax associated lymphoma and a primary effusion lymphoma as a cause of such effusions.(5) We report a case series of 5 such patients of NHL,four of which received chemotherapy with standard CHOP regimen.However,all patients succumbed.The common ndings of strikingly raised uid adenosine deaminase(ADA) levels in all of these effusions establishes a possible etiopathological link(ENBL).(6) An immunocompetent status renders primary effusion lymphoma unlikely which also has high uid ADA levels.This case series proposes a rational approach towards such cases of suspected ENBL presenting with acute onset lymphocytic polyserositis and a negative HIV antibody status with enormously raised uid ADA levels thereby permitting timely institution of chemotherapy for a better patient prognosis.


2021 ◽  
Vol 9 (3) ◽  
pp. 184-186
Author(s):  
Aditya MG ◽  
Raisa NS ◽  
Pratik A

Primary lymphoma of bladder is a very rare entity with a 0.2% incidence of all bladder malignancies. Secondary bladder involvement in malignant lymphoma is more common (10-25%) with preponderance in middle aged females. A non-Hodgkin lymphoma of the bladder can be managed conservatively without surgery and has a better prognosis. Because the presenting symptoms and radiological imaging cannot conclusively rule out a primary bladder lymphoma from other malignant causes, cystoscopy and biopsy with immune-histochemical staining is essential. We present to you a 72-year-old male with complaints of irritative lower urinary tract symptoms and asymptomatic microhematuria. On evaluation computerized tomography (CT) was s/o a large bladder wall mass with bilateral mild hydroureteronephrosis and enlarged pelvic lymphnodes. Cystoscopy and biopsy was done and the report came out to be a non-Hodgkins lymphoma. Whole body positron emission tomography (PET) scan was done which confirmed it to be a primary bladder NHL. Patient was treated with chemotherapy and is now doing well on follow up. We would like to share our experience in managing this case.


Author(s):  
Darshana Kottahachchi ◽  
Chamila Nandasena ◽  
Sachini Gallage ◽  
Sasikala Suresh

Author(s):  

This is a case of upper limb deep vein thrombosis in a HIV positive patient who had also been diagnosed of Non-Hodgkins Lymphoma. This case highlights the importance of thromboprophylaxis and thrombotic risk assessment in all HIV positive as well as cancer patients particularly in low resource setting which are at risk of increased morbidity and mortality.


2020 ◽  
Vol 11 (e) ◽  
pp. e152.1-e152.5
Author(s):  
Shibani Bhatia ◽  
Ananth Pai ◽  
Raghavendra Rao ◽  
Srilatha Parampalli Srinivas ◽  
Varsha M Shetty

Bendamustine has become a popular cancer chemotherapeutic agent in the last couple of years. It has replaced some traditional chemotherapy regimens due to its favorable side effect profile. Various cutaneous side effects have been noted following bendamustine usage. These cutaneous eruptions are to known to occur in 15-24% of patients. Benign cutaneous events include lichenoid drug eruptions, flagellate dermatoses and polymorphic papules and plaques in exposed areas. Rarely, severe adverse cutaneous reactions such as Steven Johnson syndrome, drug rash with eosinophilia and systemic symptoms and toxic epidermal necrolysis have been reported. We report a case of a 48 year-old-female who developed an insect bite like rash after initiation of bendamustine for non-Hodgkins lymphoma.


2020 ◽  
Author(s):  
Yue He ◽  
Wenqiang Tao ◽  
Dexiang Ji ◽  
Wei Lu ◽  
Yu Xiong ◽  
...  

Abstract Background: With the advent of rituximab, RCHOP is considered the appropriate chemotherapy for aggressive or advanced stage indolent B-cell Non-Hodgkins Lymphoma(NHL). RCHOP-14 seems to achieve better outcomes than RCHOP -21 in aggressive or advanced stage indolent B-cell NHL patients in recent years.Methods: To verify the befitting chemotherapy regimens for B-cell NHL patients, we searched the electronic databases for relevant English-language literature published through January 2020. The primary outcomes were complete response(CR),progression-free survival (PFS), overall survival(OS), and Adverse events (AEs). Six eligible Phase II and III clinical randomized controlled trials (RCTs) and two high-quality observational comparative studies (OCSs)were extracted, and 5565 B-cell NHL patients involved in evaluable.Results: The analysis demonstrated no significant difference for CR rate (OR= 0.98,95%CI 0.77-1.24,P=0.85)between RCHOP-14 and RCHOP-21. Compared with RCHOP-21, the merged hazard ratio (HR) for PFS and OS was, respectively, 0.94 (95% CI: 0.84-1.06, P=0.32) and 0.91(95% CI: 0.83-1.01, P= 0.08) after treatment with RCHOP-14.A subgroup analysis based on the international prognostic index(IPI) score showed that both chemotherapy regimens were applicable in B-cell NHL patients with different prognosis. The frequency of toxic side-effects was similar between schemes.Conclusions: Therefore, the data presented suggest that the efficacy and safety of both regimens are comparable and that R-CHOP14 remains a viable plan in B-cell NHL patients who prefer a shorter therapy course.


Sign in / Sign up

Export Citation Format

Share Document